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Transcription elongation regulates the expression
of many genes, including oncogenes. Histone
deacetylase (HDAC) inhibitors (HDACIs) block
elongation, suggesting that HDACs are involved in
gene activation. To understand this, we analyzed
nascent transcription and elongation factor binding
genome-wide after perturbation of elongation with
small molecule inhibitors. We found that HDACI-
mediated repression requires heat shock protein 90
(HSP90) activity. HDACIs promote the association
of RNA polymerase II (RNAP2) and negative elonga-
tion factor (NELF), a complex stabilized by HSP90,
at the same genomic sites. Additionally, HDACIs
redistribute bromodomain-containing protein 4
(BRD4), a key elongation factor involved in enhancer
activity. BRD4 binds to newly acetylated sites, and its
occupancy at promoters and enhancers is reduced.
Furthermore, HDACIs reduce enhancer activity, as
measured by enhancer RNA production. Therefore,
HDACs are required for limiting acetylation in gene
bodies and intergenic regions. This facilitates the
binding of elongation factors to properly acetylated
promoters and enhancers for efficient elongation.INTRODUCTION
Transcription elongation is a critical step in regulating many hu-
man genes (Adelman and Lis, 2012; Gilchrist et al., 2010). We
have reported previously that inhibition of histone deacetylase
(HDAC) activity results in a dramatic decrease in transcription
elongation efficiency at multiple genes using global run-on
sequencing (GRO-seq) (Core et al., 2008) to analyze RNA poly-
merase II (RNAP2) activity across the genome. We found that
elongation repression occurs in several cell lines derived from
both non-cancerous tissue and tumors, suggesting that this is
a general effect of inhibiting HDACs in human cells (Kim et al.,
2013). As a pivotal determinant of transcript level for many onco-
genes, elongation is being investigated for cancer therapy1444 Cell Reports 13, 1444–1455, November 17, 2015 ª2015 The Aubecause it is regulated bymany factors targetable by small mole-
cule inhibitors (Delmore et al., 2011; Zhai et al., 2002; Zuber et al.,
2011). HDAC inhibitors (HDACIs) are used clinically in tumor
treatment and inhibit the zinc-dependent HDAC isoforms, which
are often components of complexes associated with transcrip-
tional silencing.
Transcription of protein-coding genes by RNAP2 can be regu-
lated at initiation and elongation steps (Adelman and Lis, 2012).
Initiation of transcription is catalyzed by the assembly of the pre-
initiation complex at the promoter (Thomas and Chiang, 2006),
followed by the incorporation of the first several nucleotides
downstream from the promoter (Core et al., 2008). Transcription
through the gene body by the RNAP2 is prevented by factors that
block elongation, such as negative elongation factor (NELF) and
dichloro-1-b-D-ribofuranosylbenzimidazole (DRB)-sensitivity
inducing factor (DSIF) (Kwak and Lis, 2013). For RNAP2 to tran-
sition into the productive elongation phase and synthesize full-
length pre-mRNA, elongation-inducing factors are recruited.
Positive transcription elongation factor b (P-TEFb), which mod-
ifies RNAP2 and other factors required for overcoming the elon-
gation block, is recruited by BRD4, an acetyl-lysine binding
protein (Jang et al., 2005; Yang et al., 2005). P-TEFb contains
cyclin-dependent kinase 9 (CDK9), which phosphorylates
DSIF, NELF, and serine 2 of the heptad repeats in the C-terminal
domain (CTD) of the largest subunit of RNAP2 (Fujinaga et al.,
2004). NELF can interact with nascent RNAs and is evicted
when elongation is induced (Yamaguchi et al., 1999), whereas
DSIF travels along with the elongating RNAP2 upon phosphory-
lation by P-TEFb (Wu et al., 2003).
It was surprising that HDACIs are capable of directly repres-
sing the transcription of many genes (Chou et al., 2011; Kim
et al., 2013; Scott et al., 2002), given that classical HDACs are
components of complexes known to silence transcription. The
two inhibitors used here, trichostatin A (TSA) and suberanilohy-
droxamic acid (SAHA, known clinically as vorinostat), inhibit
the 11 classical HDAC isoforms (Bolden et al., 2006). They are
found in the Sin3, nucleosome-remodeling deacetylase
(NuRD), and nuclear receptor corepressor 2/silencing mediator
for retinoid or thyroid hormone receptors (NCOR2/SMRT) com-
plexes (Glass and Rosenfeld, 2000). Lysine acetylation is a
well-known mark of transcriptionally active open chromatin
(Eberharter and Becker, 2002), and acetylation of many tran-
scription factors activates their function, and deacetylationthors
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Figure 1. HDACIs Block Elongation of RNAP2 Transcription in the Genes They Repress
(A) Metagene plots of GRO-seq RPKM in the sense direction for repressed genes in BT474 cells. Repressed genes had significantly (log-likelihood ratio p < 1020,
one GRO-seq experiment) reduced RPKM in the gene body (300 bp downstream of TSSs to gene ends). 6,354 repressed genes were analyzed for TSA and 7,389
for SAHA.
(B) Same as (A) for MCF10A cells. There were 3,866 repressed genes for TSA and 4,643 for SAHA.
See Figure S1 for GRO-seq statistics, RNAP2 ChIP-seq, GRO-seq of a shorter treatment of SAHA in BT474 cells, SAHA blocking elongation in another cell line,
and validation that SAHA and TSA repress transcription through their effects on HDACs. See Table S1 for the number of genes common to each expression
change subgrouping between the GRO-seq shown here and previously published GRO-seq data. See Table S2 for median fold changes in subclassifications of
gene expression changes for different factors by ChIP-seq in promoter regions. See Table S3 for median fold changes in subclassifications of gene expression
changes for different factors by ChIP-seq in gene body regions.represses their function (Sterner and Berger, 2000). However, in
support of a role for HDACs in active transcription, prior research
has shown that HDAC complexes are involved in both repression
and activation of transcription in yeast (Vidal and Gaber, 1991;
Vidal et al., 1991; Wang et al., 2002), and some transcription
factors are activated when deacetylated (Chen et al., 1999;
Wolf et al., 2002; Xu et al., 2003). These proteins appear to facil-
itate similar opposing functions in higher eukaryotes as well
because HDACs are associated strongly with actively tran-
scribed genes in human cells (Wang et al., 2009).
Enhancers are transcriptional regulatory elements that pro-
mote the transcription of a gene or genes (Moreau et al., 1981;
Shlyueva et al., 2014). From a linear perspective of DNA
sequences, they are often located far away from the transcrip-
tion start sites (TSSs) of genes, but folding and looping of the
chromosome can bring these elements into close proximity of
the genes whose transcription they affect (Jin et al., 2013).
Recently, active enhancers have been found to be sites of bidi-
rectional transcription and create unstable transcripts called
enhancer RNA (eRNA). eRNAs are reliable markers of active en-
hancers (Danko et al., 2015), and the amount of eRNA produced
relates to the activity of the enhancer. Knockdown of eRNAs
reduces the transcription of the target genes of an enhancer
(Banerjee et al., 2014; Hsieh et al., 2014; Melo et al., 2013).
BRD4 is strongly associated with enhancers, and repression of
BRD4 results in a block of elongation in target genes of
enhancers (Love´n et al., 2013). NELF may be involved in the
link between enhancers and the promoters they induce as well
because it has an RNA-interacting domain that binds paused
transcripts and, potentially, eRNAs as well (Yamaguchi et al.,
1999, 2002). It has been postulated that the NELF-induced elon-
gation block is overcome when the RNA-interacting domain
exchanges the paused transcript for an eRNA (Schaukowitch
et al., 2014).
In this study, we set out to investigate the positive effect of
HDACs on transcription elongation. Our data show that HDAC-
regulated transcription elongation requires heat shock proteinCell Rep90 (HSP90) activity. In contrast, the elongation block that results
from CDK9 inhibition does not, suggesting that CDK9 functions
downstream of HDACs and HSP90. Treatment with HDACIs
causes redistribution of other elongation factors across the
genome. Particularly, colocalization of RNAP2 with the NELF
complex across the genome, whose stability is regulated by
the HSP90 chaperone, is increased strongly after HDACI treat-
ment. These inhibitors induce global acetylation changes, which
redistributes BRD4 binding, an important factor involved in pro-
moting enhancer activity, and affects the regulatory organization
of the genome. Because BRD4 and NELF are associated with
enhancers, we looked at enhancer activity after HDACI treat-
ment. We found that HDACIs reduce eRNA synthesis at high
eRNA-producing enhancer sites. This is associated with corre-
sponding changes in the expression of neighboring genes. Over-
all, we show that HDACs are important regulators of elongation
and play an essential role in active gene transcription for many
genes.
RESULTS
HDAC Inhibition Blocks Elongation of RNAP2
HDACIs repress transcription by blocking elongation, aswe have
shown previously in human breast cancer (BT474) and non-
cancerous breast epithelial (MCF10A) cell lines using GRO-seq
(Kim et al., 2013). Analysis of expression within different gene
regions by reads per kilobase of annotated region per million
mapped sequence reads (RPKM) normalization indicates that
repressed genes have an impediment in the transcription of
gene bodies, but the transcription near the start of genes is not
changed significantly or is increased after 4-hr treatment with
either of two pan-specific HDACIs, TSA and SAHA, in BT474
(Figure 1A; Figure S1A) and MCF10A (Figure 1B; Figure S1A)
cells. GRO-seq gene body RPKM was used to classify genes
into three groups based on expression changes in response to
HDACIs. Genes whose expression goes down after SAHA treat-
ment were defined as repressed, genes whose expression isorts 13, 1444–1455, November 17, 2015 ª2015 The Authors 1445
unchanged were identified as not changed, and genes whose
expression is increased were defined as activated. There is a
high percentage of overlap between genes in the three expres-
sion change groupings seen in these data compared with
GRO-seq data generated previously (Kim et al., 2013) in these
cell lines (Table S1). Chromatin immunoprecipitation sequencing
(ChIP-seq) of RNAP2was conducted to validate the three group-
ings, and we found that SAHA does not significantly change the
density of RNAP2 in the promoters of repressed genes (Fig-
ure S1B; Table S2). In the gene body, RNAP2 binding decreases
in GRO-seq-repressed genes, stays the same in unchanged
genes, and increases significantly in activated genes (Fig-
ure S1B; Table S3).
To examine the kinetics by which HDACIs suppress transcrip-
tion elongation, the effect of SAHA treatment for a shorter time
was examined in BT474 cells with GRO-seq. SAHA represses
genes via an elongation block even after a short 30-min treat-
ment and resulted in a similar, although less intense global
pattern of elongation inhibition as the 4-hr treatment (FiguresS1C
and S1D). To test whether the repressive effect of SAHA on tran-
scription elongation is applicable to cells of a different origin, we
applied SAHA to a neuroblastoma cell line, SK-N-SH, and exam-
ined the transcription elongation pattern. SAHA blocked elonga-
tion in SK-N-SH cells (Figure S1E), underscoring the general
applicability of HDACIs as transcription elongation blockers.
Overall, our data show that HDAC inhibition blocks the transition
of RNAP2 into productive elongation in HDACI-repressed genes
in a short time window and in a broad cellular context.
We examined whether overexpression of the HDAC1 isoform
can rescue the effect of SAHA to validate that HDACIs are inhib-
iting the intended target and that HDACIs are causing repression
through a block in the catalysis of deacetylation. We overex-
pressed recombinant HDAC1 wild-type (WT) and catalytically
dead mutant (mut; Figure S1F), and examined the expression
of two well characterized HDACI-repressed oncogenes regu-
lated by elongation in BT474 cells, ERBB2 and MYC (Kim
et al., 2013). Overexpression of the WT HDAC1 isoform, but
not mut, in BT474 cells antagonizes SAHA-mediated repression
of these two oncogenes (Figure S1G). TSA is also antagonized
by HDAC1 overexpression, and the effect of overexpression
could be overcome by increasing the dose of the drug (Fig-
ure S1H). This demonstrates that HDACIs are repressing tran-
scription by blocking the deacetylation catalyzed by HDAC1,
a class I deacetylase, and, possibly, other isoforms. Further-
more, ChIP-seq analysis of HDAC1 shows that, prior to drug
treatment, this enzyme is more enriched in genes that can be
repressed by SAHA treatment compared with genes that do
not change their expression after SAHA (Figure S1I; comparison
of DMSO samples). Together, these data suggest that genes that
are repressed by HDACI treatment are regulated by
deacetylation.
HDACI Repression of Transcription Requires HSP90
The HSP90 chaperone complex promotes RNAP2 pausing in
Drosophila (Sawarkar et al., 2012). Therefore, we tested whether
the mechanism of HDACI suppression of transcription elonga-
tion is dependent on HSP90. A potent HSP90 inhibitor, geldana-
mycin (GEL), was applied to reduce pausing and was used in1446 Cell Reports 13, 1444–1455, November 17, 2015 ª2015 The Aucombination with HDACIs in BT474 cells to see how these small
molecules interact to affect elongation. qRT-PCR shows that
ERBB2 and MYC repression by HDACIs is antagonized by GEL
treatment (Figure 2A), whereas RPS10 and ACTG1, which are
not repressed by HDACIs, do not show a significant increase
in expression after combination treatment (Figure S2A). To look
at the global elongation changes brought on by the drug combi-
nations, we conducted GRO-seq with single and combined
treatment with the inhibitors. As expected, treating with GEL
alone reduces the amount of promoter-proximal transcripts in
both the BT474 and MCF10A cell lines (Figures 2B and 2C; Fig-
ure S2B), validating this treatment as a repressor of pausing.
GEL antagonizes the repression of the majority of the top
1,000 HDACI-repressed genes (Figures 2D and 2E) more than
5-fold (Figure S2C). Combination treatment with GEL an-
tagonizes the gene body repression induced by HDACIs
(Figures 2F and 2G; Figure S3D). These results show that
HDACI-mediated repression of elongation is dependent on
HSP90 activity.
NELFE, a subunit of the NELF complex, is destabilized upon
HSP90 inhibition in cells from several organisms (Sawarkar
et al., 2012). Destabilization of just one subunit of the four-sub-
unit NELF complex leads to the degradation of the entire com-
plex (Narita et al., 2007; Sun and Li, 2010; Sun et al., 2008).
We tested whether NELF is a downstream effector of HSP90
that could be mediating transcriptional elongation repression
by HDACIs. In BT474 cells, GEL destabilizes the NELFA subunit
(Figure 3A), which likely leads to the destabilization of the entire
NELF complex. To examine the change in binding of NELF upon
HDACI treatment, we performed ChIP-seq of NELFA and HSP90
in DMSO- and SAHA-treated BT474 cells. NELFA and HSP90
density are correlated in promoters and gene bodies, with a
stronger correlation in gene bodies (Figure 3B). More than half
of RNAP2 binding peaks are not colocalized with NELFA in the
DMSO treatment control. In contrast, SAHA treatment dramati-
cally increases the number of NELFA peaks, and these peaks
predominantly overlap with RNAP2 (Figure 3C). These results
show that the global distribution of NELF binding is affected by
SAHA, indicating that HDACI treatment may result in transcrip-
tion pausing through NELF.
P-TEFb Inhibition Affects Transcription Elongation, but
Not through HSP90
P-TEFb is an important regulator of elongation, so we sought to
determine how P-TEFb might act in connection with HDACs
and HSP90. In addition to the HSP90 inhibitor GEL, we used
the elongation inhibitor flavopiridol (FLAVO), which inhibits the
CDK9 subunit of the P-TEFb complex. We aimed to compare
its effects on elongation with HDACI and GEL combination
treatment. Like HDACIs, FLAVO represses ERBB2 and MYC
transcript levels in BT474 cells (Figure S3A). Globally, FLAVO-
repressed genes show a decrease in gene body transcription
in GRO-seq experiments. However, unlike HDACI-repressed
genes, FLAVO-repressed genes displayed a dramatic increase
in promoter-proximal transcription (Figures 4A and 4B; Fig-
ure S3B). Furthermore, transcription in the gene bodies of
FLAVO-repressed genes in BT474 and MCF10A cells is still
repressed in the presence of GEL (Figures 4C and 4D;thors
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Figure 2. Inhibition of HSP90 Antagonizes HDACI Repression
(A) mRNA level of HDACI-repressed genes in combination with GEL. Quantitation of ERBB2 and MYC mRNA relative to GAPDH in BT474 cells after single and
combined treatments is shown. Statistical significance was determined with a two-tailed t test. ***p < 0.001; **p < 0.01; and n.s., not significant (p > 0.05). Error
bars represent SE. n = 11–14 from at least four biological replicates. GEL was administered at 20 mM.
(B) GRO-seq metagenes of GEL treatment for all genes in BT474 cells. One GRO-seq experiment was conducted. 37,467 genes are represented in the metaplot.
(C) Same as (B) for MCF10A cells.
(D) Heatmaps of the top 1,000 TSA- and SAHA-repressed genes in BT474 cells as determined byGRO-seq and those same geneswhenGELwas also added. The
magnitude of expression for HDACIs was calculated relative to DMSO, and HDACI + GEL was relative to GEL. The colors represent the magnitude expression
change in log scale, with red representing repression and blue activation.
(E) Same as (D) for MCF10A cells.
(F) Metagenes of HDACI-repressed genes in BT474 cells when GEL was also added (same genes as in Figure 1A).
(G) Same as (F) for MCF10A cells (same genes as in Figure 1B).
See Figure S2 for qRT-PCR of genes not repressed by HDACIs after combination treatment, GRO-seq statistics, and percentages of genes antagonized by GEL.Figure S3B), whereas the transcription of HDACI-repressed
genes was recovered by GEL treatment (Figures 2D and 2E;
Figure S2C). Elongation patterns observed in GRO-seq were
examined after combined treatment with these drugs. The
FLAVO-induced elongation repression pattern persists in the
presence of GEL (Figures 4E and 4F; Figure S3B), suggesting
that its mechanism of repression is HSP90-independent. This
shows that HDACI-mediated transcription suppression occurs
through a different mechanism than FLAVO. Perhaps FLAVO
suppresses elongation via more immediate effects on the phos-Cell Repphorylation of RNAP2 CTD than HDACIs, which suppress
genes under tight control of HSP90.
Acetylation and BRD4 Binding Changes in Gene Bodies
and Intergenically after HDACI
HDACI treatment globally increases acetylation, and we pre-
dicted that this results in changes in the distribution of the bind-
ing of key acetylated histone readers such as BRD4. This protein
acts as a scaffold to recruit elongation factors, so its redistribu-
tion would lead to changes in the binding of other proteins.orts 13, 1444–1455, November 17, 2015 ª2015 The Authors 1447
AB
C Figure 3. HSP90 Stabilizes NELFA, and
SAHA Increases NELFA Binding
(A) NELFA stability after treatment with different
elongation-affecting drugs, shown with western
blot of BT474 cell lysates (representative image for
one of two blots).
(B) Correlation of NELFA and HSP90 fold enrich-
ments in promoter and gene body regions for
33,119 annotated RefSeq genes. Two biological
replicates for each ChIP-seq were conducted, and
the average signal is plotted.
(C) Venn diagrams of RNAP2 and NELFA peak
overlaps. Overlaps were within a 500-bp window.
The numbers of genes in each section are shown.ChIP-seq shows that the acetylation of lysines in histone H3K27
(H3K27Ac), H3 (H3Ac), and H4 (H4Ac) is reduced in promoter-
proximal regions, whereas, in gene bodies, acetylation increases
after SAHA treatment (Figure 5A). Consistent with the changes in
acetylation, SAHA treatment decreases the binding of BRD4
near TSSs and increases its binding in gene bodies (Figure 5B;
Tables S2 and S3). BRD4 is enriched in repressed genes more
than in unchanged genes in BT474 cells without inhibitor treat-
ment, suggesting that their transcription is regulated by BRD4
under normal conditions, unlike the unchanged genes.
Interestingly, we noticed that, in gene coding regions,
although the magnitude of BRD4 binding and acetylation may
differ, the locations of detected peaks did not show many
changes upon SAHA treatment (Figure 6A). In intergenic regions,
however, there are muchmore striking changes in the location of
peaks, and there is an increase in the number of peaks by SAHA
treatment (Figure 6B), suggesting that HDACIs may affect the
global chromatin landscape far beyond regions encoding genes.
To investigate whether changes in BRD4 binding are corre-
lated with changes in acetylation, we identified whether peaks
weremaintained after SAHA treatment.We identified sites where
BRD4 binding peaks were lost (only present in DMSO), overlap
(present in both DMSO and SAHA), and gained (only present
after SAHA treatment). We determined the magnitude of change
in the acetylation and binding at these sites. As expected, BRD4
binding is reduced at sites where BRD4 is lost, stays the same at
overlapping sites, and increases at gained sites (Figure 6C). At
these same sites, the level of acetylation is similar at lost and
overlap sites but displays far greater increases at gained sites
(Figure 6D). Therefore, BRD4 is being recruited to newly created
sites of acetylation in intergenic regions. Loss of BRD4 binding at
certain sites after SAHA treatment may be due to newly created
acetylated sites competing for the binding of this protein.
JQ1, a BRD4 inhibitor, and HDACIs share similar gene expres-
sion change profiles (Bhadury et al., 2014). To see which genes
weremutually affected by BRD4, HDAC, or P-TEFb inhibition, we
defined the top 1,000 most repressed genes for each drug and1448 Cell Reports 13, 1444–1455, November 17, 2015 ª2015 The Authorsdetermined the percentage of genes the
inhibitors were able to repress in pairwise
combinations. The percentage of genes
shared between JQ1 and the HDACIs is
similar to the percentage shared between
the two related HDACIs, TSA and SAHA.FLAVO does not have as large of an overlap with HDACIs as
JQ1, indicating more similarity between the effects of BRD4
and HDAC inhibition than P-TEFb inhibition (Figure S4A).
Concordantly, JQ1 represses ERBB2 and MYC in BT474 cells
(Figure S4B). This drug also represses elongation in a pattern
similar to HDACIs in our two cell lines (Figures S4C and S4D).
This indicates that JQ1 and HDACIs may have a similar mecha-
nism of action.
eRNA Transcription Is Repressed by HDACIs
BRD4 is bound at active enhancers (Chapuy et al., 2013), and it
has been found recently that JQ1 reduces eRNA synthesis
(Kanno et al., 2014). Because restructuring of acetylation and
BRD4 binding occurs in intergenic regions, we wondered
whether HDACI treatment could be affecting positive regulators
of transcription located in intergenic regions, namely enhancers,
via loss of BRD4 at pertinent enhancer sites. We used a predic-
tionmethod similar to the one defined by theOzato group (Kanno
et al., 2014) to find eRNA-generating sites by determining inter-
genic BRD4 peak locations in BT474 cells from ChIP-seq and
characterized the level of eRNA synthesis around them (Fig-
ure 7A). As validation, we showed that the enrichment of
H3K27Ac, a mark of active enhancers, is higher at predicted
enhancer sites than at annotated promoters (Figure 7B). The
expression of the most highly expressed eRNAs from a 4-hr
DMSO treatment were analyzed in comparison with their expres-
sion after different inhibitor treatments (Figure 7C). JQ1, as ex-
pected from previous reports, reduced eRNAs. HDACIs did as
well, and to an even greater extent. Even after only 30 min of
SAHA treatment, the inhibitor was able to reduce eRNAs
(Figure S5A), showing that this treatment causes fast action at
enhancers. Both BRD4 and HDACs are therefore positive regu-
lators of enhancer activity, possibly through effects of HDACIs
on BRD4 binding (Figure 6; Figure S5B). In contrast, FLAVO
did not decrease the median eRNA synthesis level at enhancers,
suggesting that eRNA transcription is P-TEFb-independent.
Surprisingly, GEL treatment is a strong repressor of eRNA
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Figure 4. Elongation Block Caused by P-TEFb Inhibition Is Not Dependent on HSP90
(A) FLAVO-repressed (log-likelihood ratio p < 1020 for gene body RPKM changes, 9,706 genes) metagenes from BT474 cells. Data are from one GRO-seq
experiment.
(B) Same as (A) for MCF10A cells (12,659 genes).
(C) Heatmaps of the expression changes in the top 1,000 FLAVO-repressed genes with the greatest magnitude of change in BT474 cells, as determined by GRO-
seq (log-likelihood ratio p < 1020), and those same genes when GEL was also added. The colors indicate the magnitude expression change in log scale. Red
represents repression and blue activation.
(D) Same as (C) for MCF10A cells.
(E) Metagenes of all FLAVO-repressed genes when GEL was also added to BT474 cells.
(F) Same as (E) for MCF10A cells.
See also Figure S3 for FLAVO repression of ERBB2 and MYC and GRO-seq statistics.synthesis, indicating that HSP90 is necessary for enhancer func-
tion and, possibly, linking NELF to enhancer function because of
the effect HSP90 has on NELF stability. As in the BT474 cell line,
HDACI treatment reduces eRNAs in MCF10A cells, as do JQ1
and GEL. FLAVO, again, does not repress eRNAs (Figure S5C),
demonstrating that the effect of HDACI on enhancers is not can-
cer-specific. We tested whether these enhancers are regulating
genes nearby because, although enhancers can work from a
great distance, they often regulate nearby genes. We looked at
the percentage of genes near eRNA sites that are reduced signif-
icantly by inhibitor treatment. We found that, compared with the
percentage of all genes that are repressed by an inhibitor, there
is a higher percentage of genes repressed that are located near
downregulated eRNA sites (Figure 7D; Figure S5D). This sug-
gests that the eRNA activity level affects target gene expression
and shows that enhancer activity is dependent on HDACs.
DISCUSSION
The repression of transcription by HDACIs in many genes is
counterintuitive because of the well-known role HDACs play in
turning off transcription. We have shown that HDACIs cause a
block in the elongation step of transcription by RNAP2. Some
studies show evidence to support this finding. First, HDACs
bind to highly expressed genes more than to lowly expressedCell Repgenes and heterochromatin, suggesting that they play a role in
active gene transcription (Wang et al., 2009). This is in line with
our previous finding that HDACIs target the most highly ex-
pressed genes for repression (Kim et al., 2013). Second, sin-
gle-cell imaging experiments show that, shortly after induction
of transcription initiation, acetylation of histones is decreased
around the time that the elongating form of RNAP2 is detected
(Stasevich et al., 2014). The deacetylation caused by classical
HDACs post-initiation is likely an important step in inducing
gene body transcription and may suggest that cycling of acety-
lation and deacetylation is important in the process of transcrip-
tion elongation (Wang et al., 2009).
Based on our analysis, HDACs are required for the removal
of acetylation marks in gene bodies and intergenic regions,
where their levels are lower than at promoters and enhancers.
We know that, in yeast, the RPD3 deacetylase, related to
class I HDACs in humans, acts to specifically deacetylate
gene bodies. It is recruited by the histone H3 lysine 36 methyl-
ation (H3K36me) mark, which is deposited cotranscriptionally
along with the elongating RNAP2 (Carrozza et al., 2005; Joshi
and Struhl, 2005). When the cell is unable to deacetylate these
sites because of the presence of HDACIs, the acetylation
enriched near promoters and enhancers may no longer serve
to demarcate these regulatory regions from the rest of the
genome. BRD4, which is lost at promoters and redistributedorts 13, 1444–1455, November 17, 2015 ª2015 The Authors 1449
AB
BT474 ChIP-seq
BT474 ChIP-seq
Figure 5. HDACIs Affect Acetylation of
Histones and BRD4 Binding
(A) ChIP-seq profiles of acetylated histone tails
around TSSs of repressed genes and their
enrichment in promoters and gene bodies.
Average acetyl-ChIP-seq profiles from two bio-
logical replicates are averaged and normalized to
the average yield of both replicates. The H3Ac
antibody recognizes acetylated K9 and K14 in the
H3 subunit. The H4Ac antibody recognizes acet-
ylated K5, K8, K12, and K16 in the H4 subunit.
(B) BRD4 binding at TSSs and in gene bodies of
repressed genes. Quantitation of their binding in
repressed and unchanged genes is shown in
boxplots. The statistics reported are from Wil-
coxon rank-sum tests. Horizontal lines on the
boxplot graphs represent the median signal in all
genes from the chromatin input sample. Shown is
the average of two replicates.intergenically after HDACI treatment, is important in the recruit-
ment of elongation factors to appropriate locations to activate
transcription. Indeed, HDACs are required for BRD4-inducible
transcription in human cell lines (Hu et al., 2014). The reduction
in BRD4 likely leads to the reduction of the factors it recruits,
such as P-TEFb, at promoters after HDACI treatment. Other
elongation factors may also redistribute in response to BRD4
binding to inappropriate acetylation marks when HDACs are1450 Cell Reports 13, 1444–1455, November 17, 2015 ª2015 The Authorsnot able to maintain a lower level of
acetylation at specific sites. More work
is required to determine whether BRD4
binding partners are responsible for the
block in elongation after applying
HDACIs or whether BRD4 redistribution
itself exerts this effect on elongation.
HDACIs appear to work upstream of
P-TEFb and require HSP90 activity.
HDAC inhibition affects NELF binding,
and HDACIs cannot repress transcription
in the presence of GEL. This may be
through the stabilization of the NELF
complex as well as effects on other client
proteins of HSP90 involved in elongation
(Schaaf et al., 2013; Zhou et al., 2015).
Although there are multiple known acety-
lation sites on HSP90, all seem to reduce
the interaction of HSP90 with client pro-
teins (Kovacs et al., 2005; Scroggins
et al., 2007; Yang et al., 2008), opposite
of what would be expected based on
the results reported here. HDACIs have
also been shown to change the levels of
reactive oxygen species in the cell, which
induces some HSP90 degradation (Park
et al., 2015), but this, again, contradicts
the increase in NELF binding after HDACI
treatment. So it may be that HDACIs
regulate elongation by directly affectingNELF or other elongation factors and that these factors require
HSP90 to stabilize them. Whether there are intermediate steps
between HDAC function and NELF activity is unknown.
Here we report that eRNA production is reduced when HDACs
are inhibited. They are also reduced when HSP90, which is
responsible for NELF stability, is repressed. This may further
explain how HDACIs repress transcription because enhancer
function and elongation are possibly linked via NELF function
AB
C D
BT474 ChIP-seq peaks in coding regions
BT474 ChIP-seq peaks in intergenic regions
BT474 ChIP-seq BT474 ChIP-seq
Figure 6. Intergenic Changes in BRD4 Binding and Corollary Changes in Histone Acetylation
(A) Peaks and their overlaps before and after SAHA treatment in coding regions for acetylated histones and BRD4 in BT474 cells.
(B) Peaks and their overlaps before and after SAHA treatment in intergenic regions for acetylated histones and BRD4 in BT474 cells. The number of peaks in each
category is listed. Only peaks present in both replicates were considered.
(C) Within intergenic BRD4 binding sites, those that are lost upon SAHA, stay bound, and are gained after SAHA are analyzed for intensity of BRD4 binding
changes.
(D) Acetylation changes at intergenic BRD4 binding sites.
See also Figure S4 for the overlap of genes affected by TSA, SAHA, JQ1 (BRD4 inhibitor), and FLAVO treatments and JQ1 effects on ERBB2 andMYC expression
and elongation.(Schaukowitch et al., 2014). Further analysis of which genes
these enhancers regulate is required to fully understand the ef-
fects HDACs and NELF have on enhancer activity.
Going forward, it will be important to identify relevant targets of
acetylation that are necessary for transcriptional activation by
HDACs in histones or other proteins because deacetylation of
non-histone substrates may also be involved in promoting tran-
scription elongation. A large amount of lysine acetylation events
on non-histone substrates have been identified globally using
mass spectrometry, and BRD4, several HDAC isoforms, SPT5
(a DSIF component), and NELFB all have acetylated lysines
(Choudhary et al., 2009) that could have effects on elongation.
Functional analysis of these sites will help determine how they
affect this pathway. Also, biochemical analysis of elongation fac-
tors after HSP90 inhibition would be beneficial to elucidate how
this factor affects their stability and function.
HDACIs are an effective treatment for several types of cancer
(Federico and Bagella, 2011). These drugs globally increase acet-
ylation,which is oftenassociatedwith an increase in the transcrip-Cell Reption level of many genes, and they increase the expression of
many important cell cycle arrest and apoptotic genes (Xu et al.,
2007). In contrast, we have also found that many oncogenes are
selectively targeted for repression by HDACIs through effects on
elongation because of their high level of transcription (Kim et al.,
2013). The elongation pathway may be a very useful therapeutic
target for cancer because other elongation-inhibiting drugs, like
FLAVO and JQ1, have also shown promise as cancer treatments
(Filippakopoulos et al., 2010; Patel et al., 1998; Zuber et al., 2011).
Understanding themechanismbywhichHDACIsstrengthenelon-
gation blocksmay facilitate the development of treatments able to
more specifically target genes for therapeutic repression.EXPERIMENTAL PROCEDURES
Cell Culture
MCF10A, BT474, and SK-N-SH cells were obtained from the American Type
Culture Collection (ATCC) and cultured according to their suggested
conditions.orts 13, 1444–1455, November 17, 2015 ª2015 The Authors 1451
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Figure 7. eRNA Expression Is Reduced by HDACIs
(A) BRD4 intergenic binding sites were defined, and GRO-seq reads were aligned to a 1,000-bp window around the center of the peak. The top 500 most
expressed eRNAs were identified in a DMSO GRO-seq experiment and analyzed in DMSO and under different drug conditions.
(B) Enrichment of H3K27Ac at predicted enhancer sites compared with annotated promoters.
(C) Boxplot of eRNA expression after different drug treatments. Statistics are from Wilcoxon rank-sum tests.
(D) Percentage of genes that are repressed either overall or only in the genes closest to the top 100 most repressed eRNAs for each drug.
See also Figure S5 for eRNA expression changes after a 30-min SAHA treatment, the binding changes of BRD4 at predicted enhancer sites, and the changes in
eRNA production brought on by inhibitor treatments in MCF10A cells.Drug Treatments
TSA and SAHA were obtained from Sigma (SAHA lot no. 042M4740V), (S)-JQ1
was a gift from J. Bradner at the Dana Farber Cancer Institute (DFCI), FLAVO
was from Sigma (lot no. 100M4723V), and GEL was from Enzo Life Sciences
(BML-EI280).
For GRO-seq, the doses were 500 nM, 5 mM, 500 nM, 500 nM, and 10 mM for
TSA, SAHA, JQ1, FLAVO, and GEL, respectively. 4-hr treatments were done
for the elongation inhibitors TSA, SAHA, JQ1, and FLAVO, and GEL was
applied for 4 hr and 15 min (15-min pre-treatment of GEL for combined GEL
plus elongation inhibitor treatments). The 30-min SAHA treatment for GRO-
seq was the exception. 4-hr treatments were used for DMSO, SAHA, and
FLAVOChIP-seq experiments and 24-hr treatments for qRT-PCR and western
blot samples unless stated otherwise.
Expression Analysis
qRT-PCR was performed as described previously (Kim et al., 2013) except
with the ImProm-II enzyme from Promega with 4.6875 mM MgCl2 in the
reverse-transcriptase reaction. The MYC primer sequences are MYC-F
50-CTCTGACCTTTTGCCAGGAG-30 and MYC-R 50-TCCTCGGATTCTCTGC
TCTC-30.
Western Blot
Western blots were done with the same NELFA antibody as that used in ChIP-
seq or polyclonal rabbit V5 antibody from Abcam (catalog no. ab9116). BT474
cells were treated for 24 hr before lysis.
GRO-Seq
GRO-seqwas performed as described previously (Kim et al., 2013), except the
detergent concentration was optimized and libraries were multiplexed to
conduct high-throughput sequencing in one lane. Additional details can be
found in the Supplemental Experimental Procedures.1452 Cell Reports 13, 1444–1455, November 17, 2015 ª2015 The AuChIP
Chromatin was prepared and immunoprecipitated as described previously
(Kim et al., 2011), except that protein A/G dynabeads (Invitrogen) were used
instead of organism-specific secondary antibody bound beads. 25% of the
amount of chromatin was used for RNAP2 and acetyl ChIPs to reduce oversat-
uration of bead binding. Details regarding antibodies used can be found in the
Supplemental Experimental Procedures.ChIP-Seq Library Preparation
The ThruPLEX DNA-seq kit from Rubicon Genomics was used for multiplexed
ChIP-seq library prep of BT474 chromatin. Indexed samples were quantitated
with qPCR and mixed in equimolar amounts. The input sample was prepared
with an Illumina DNA-seq kit.Sequencing and Sequencing Data Analysis
The Yale Stem Cell Center Genomics and Bioinformatics Core Facility con-
ducted the sequencing on an Illumina HiSeq 2000 platform. Sequencing
data alignment and normalization are described in the Supplemental Experi-
mental Procedures.
Metagenes of GRO-seq data were generated with scripts from H. Kwak
(Kwak et al., 2013) and are shown as 25-base pair (bp) windows considering
transcript directionality. ChIP-seq metagenes were generated with our own
perl scripts, which count ChIP-seq and input reads and normalize read counts
by the total number of mapped reads in 50-bp sliding windows. Directionality
of the gene was not considered. Boxplots and Venn diagrams were created
using R version 3.1.2.
Peaks were called with MACS 1.3.7.1 (Zhang et al., 2008) with the mfold
parameter set to 10. BEDTools v2.23.0 (Glass and Rosenfeld, 2000) was
used to generate overlaps between duplicate samples and identify peaks
and signals coming from genic and intergenic regions, and the multicovthors
function was used to determine the amount of signal coming from a given
genomic region.
In BT474 cells, eRNA annotation was done by taking peaks called in model-
based analysis for ChIP-seq (MACS) for BRD4, removing regions within 1 kilo-
base of Refseq-annotated genes. BEDTools was used to find overlapping
peaks between replicates. Partek was used to find the amount of reads com-
ing from 500 bp upstream and downstream of the center of the BRD4 peaks.
The highest expressed putative eRNAs in a DMSO treatment from an indepen-
dently generated GRO-seq experiment was used to sort the highest expressed
eRNAs, and then the DMSO from the same experiment as the other treated
samples acted as the control. Genes nearest to the predicted eRNA sites
were determined using BEDTools closest function.
Statistical Tests and Categorizations
Two-tailed Student’s t tests and R2 were performed in Excel 14.4.9. Wilcoxon
rank-sum tests were performed in R version 3.1.2, and the p values reported
are not corrected for multiple testing. Statistical analysis for defining repres-
sion or activation in GRO-seq was performed using the log-likelihood ratio in
the Partek Genomic Suite, version 6.14.0220.
GRO-seq expression level change groupings for ChIP-seq were determined
by selecting significantly repressed or activated genes (log-likelihood ratio,
p < 1020) based on gene body RPKM in DMSO and SAHA treatments. Un-
changed genes were expressed in DMSO and SAHA conditions, were not
changed significantly (p > 1020), and had less than a 2-fold change in their
expression, up or down. The genes common to these categorized lists from
the GRO-seq prepared for this manuscript and the GRO-seq prepared previ-
ously (Kim et al., 2013) were used to analyze ChIP-seq data (Table S1).
Additional methods and associated references are available in the Supple-
mental Information.
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